Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

BSH 2018 | Personalized dendritic cell vaccine for acute leukemia and multiple myeloma

David Avigan • 16 Apr 2018
BSH 2018
Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Leukemia Multiple Myeloma Vaccines

In this interview, David Avigan, MD, from Beth Israel Deaconess Medical Centre, Boston, MA, discusses the exciting therapeutic area of personalized vaccines, which aim to produce tumor-specific immunity. Prof. Avigan discusses the settings that this has proven most successful in, and highlights promising pre-clinical and clinical trials. This video was recorded at the British Society for Haematology (BSH) 2018 Annual Scientific Meeting, in Liverpool, UK.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from David Avigan

Overcoming challenges in TCR mapping for personalized immunotherapy in multiple myeloma
1:09
Overcoming challenges in TCR mapping for personalized immunotherapy in multiple myeloma
David Avigan • 23 Sep 2026
Identifying tumor-reactive T-cell clones to guide personalized immunotherapy in multiple myeloma
1:25
Identifying tumor-reactive T-cell clones to guide personalized immunotherapy in multiple myeloma
David Avigan • 23 Sep 2026
Single-cell antigen & TCR mapping to investigate tumor-reactive T-cell responses in multiple myeloma
3:08
Single-cell antigen & TCR mapping to investigate tumor-reactive T-cell responses in multiple myeloma
David Avigan • 23 Sep 2026
Impact of dendritic cell fusion vaccine on the microenvironment and outcomes in multiple myeloma
2:26
Impact of dendritic cell fusion vaccine on the microenvironment and outcomes in multiple myeloma
David Avigan • 26 Aug 2022

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals